Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel

NCT06142188 is registered in ClinicalTrials.gov with Shanghai Ming Ju Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06142188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06142188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
Lead sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase
Observational
Overall status
Not yet recruiting
Start date
December 28, 2023
Completion date
December 31, 2038
Enrollment
150 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, large b-cell lymphoma, lymphoma, b-cell